Literature DB >> 6277647

Evidence against adenylate cyclase-coupled adenosine receptors in the guinea pig heart.

W Schütz, E Tuisl.   

Abstract

(--)-N6-(Phenylisopropyl)adenosine (PIA, 10 microM) and 5'-N-(ethylcarboxamide)adenosine (NECA, 50 microM), potent agonists at the adenylate cyclase-coupled R-site adenosine receptor, were investigated for adenylate cyclase inhibition in a guinea pig ventricular membrane preparation by means of the dATP assay method. Neither compound influenced basal or isoproterenol-stimulated cyclase activity, irrespective of whether Na ions were present or not. These data suggest that R-site receptors may not be involved in the cardiac adenylate cyclase system of the guinea pig.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6277647     DOI： 10.1016/0014-2999(81)90516-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  12 in total

1.  Effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a highly selective adenosine receptor antagonist, on force of contraction in guinea-pig atrial and ventricular cardiac preparations.

Authors:  H von der Leyen; W Schmitz; H Scholz; J Scholz; M J Lohse; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-08       Impact factor: 3.000

2.  Pharmacological characterization of A1 adenosine receptors in isolated rat ventricular myocytes.

Authors:  D Martens; M J Lohse; B Rauch; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

3.  Cardiac sarcolemmal purity is essential for the verification of adenylate cyclase inhibition via A1-adenosine receptors.

Authors:  W Schütz; M Freissmuth; V Hausleithner; E Tuisl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

4.  [Cardiac effects of adenosine. Mechanism of action, pathophysiologic and clinical significance].

Authors:  M Böhm
Journal:  Klin Wochenschr       Date:  1987-06-01

5.  Adenosine and adenosine analogs inhibit phosphodiesterase activity in the heart.

Authors:  W Meyer; M Nose; W Schmitz; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-12       Impact factor: 3.000

6.  Demonstration of Ri-type adenosine receptors in bovine myocardium by radioligand binding.

Authors:  M J Lohse; D Ukena; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

7.  Evidence for adenosine receptor-mediated isoprenaline-antagonistic effects of the adenosine analogs PIA and NECA on force of contraction in guinea-pig atrial and ventricular cardiac preparations.

Authors:  M Böhm; R Brückner; W Meyer; M Nose; W Schmitz; H Scholz; J Starbatty
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

8.  Evidence against the adenosine-catecholamine antagonism under in vivo conditions.

Authors:  R Seitelberger; W Schütz; O Schlappack; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

9.  Phosphorylated adenosine derivatives as low-affinity adenosine-receptor agonists. Methodological implications for the adenylate cyclase assay.

Authors:  W Schütz; G Steurer; E Tuisl; H Plass
Journal:  Biochem J       Date:  1984-05-15       Impact factor: 3.857

10.  Adenosine inhibits the positive inotropic effect of 3-isobutyl-1-methylxanthine in papillary muscles without effect on cyclic AMP or cyclic GMP.

Authors:  M Böhm; R Brückner; J Neumann; M Nose; W Schmitz; H Scholz
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.